A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

NCT05818683 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Neoplasms
Metastatic Hormone-sensitive Prostate Cancer

Interventions

DRUG: Pasritamig
DRUG: Cetrelimab
DRUG: Cabazitaxel
DRUG: Docetaxel
DRUG: Apalutamide
DRUG: Enzalutamide
DRUG: Darolutamide
DRUG: Abiraterone acetate plus prednisone (AAP)
DRUG: Lutetium Lu-177 vipivotide tetraxetan
DRUG: JNJ-101556143

Sponsor

Janssen Research & Development, LLC